Activity profiles of dalargin and its analogues in μ-, δ- and κ-opioid receptor selective bioassays
Lab research · 1999
- What was studied
- Isolated preparations from guinea pig, hamster, mouse, rat and rabbit
- Main finding
- Isolated-tissue assays showed that D-Ala configuration and other sequence modifications altered potency, peptidase resistance and receptor preference. The tested Dalargin profile favored μ activity; this does not settle receptor contributions in every tissue or disease model.
[L-Ala²] analogue · 19-fold less potent; δ/μ activity ratio 6.78; naloxone KB 7.9 nM
Reported findings and study design
Isolated animal tissues comparing Dalargin analogues at opioid-receptor assay sites.
Population or model Isolated preparations from guinea pig, hamster, mouse, rat and rabbit
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| [L-Ala²] analogue | 19-fold less potent; δ/μ activity ratio 6.78; naloxone KB 7.9 nM | |
| [Met⁵] analogue | Naloxone KB 5.5 nM | |
| Dalarginethylamide | Naloxone KB 5.0 nM | |
| N-methyl-[L-Phe⁴]-dalarginamide | δ/μ ratio 0.00053; naloxone KB 2.6 nM | |
| [D-Phe⁴] amide analogues | Inactive in the reported assays |
Each potency/ratio belongs to a particular analogue; the KB figures concern naloxone antagonism, not a Dalargin human affinity or dose.
Source for these results ↗ · Reviewed 2026-10-29
Study limitations and source details
Study limitations
- Animal-tissue bioassays, not a human efficacy or safety trial.
- Dalargin analogues are not interchangeable with the parent peptide.
Source details
Selected source text and metadata checked; full risk-of-bias review pending.
Selected text reviewed
Sources checked
Citation
N. Pencheva, J. Pospišek, L. Hauzerova, T. Barth, P. Milanov. Activity profiles of dalargin and its analogues in μ-, δ- and κ-opioid receptor selective bioassays British Journal of Pharmacology. 128(3):569–576
Study source ↗ · DOI 10.1038/sj.bjp.0702825 · Bibliography entry · Link to this summary